givinostat

Known as: Gavinostat 
An orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
0246820102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene leading to dystrophin deficiency, muscle fiber… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2014
2014
Relapsed/refractory Hodgkin’s lymphoma (HL) is an unmet medical need requiring new therapeutic options. Interactions between the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVE We aimed to compare the potential for inducing HIV production and the effect on T-cell activation of potent HDAC… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has… (More)
  • table I
  • figure 1
  • table II
  • table III
  • table IV
Is this relevant?
2013
2013
Previous work has established the existence of dystrophin-nitric oxide (NO) signaling to histone deacetylases (HDACs) that is… (More)
Is this relevant?
2013
2013
We investigated whether clinically achievable concentrations of the histone deacetylase (HDAC) inhibitors givinostat and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
We investigated the mechanism of action of the histone deacetylase inhibitor Givinostat (GVS) in Janus kinase 2 (JAK2)(V617F… (More)
Is this relevant?
2011
2011
ITF2357 (givinostat) is a histone deacetylase inhibitor with antiinflammatory properties at low nanomolar concentrations. We… (More)
Is this relevant?
2011
2011
OBJECTIVE The current treatment options for systemic-onset juvenile idiopathic arthritis (JIA) are methotrexate, steroids, and… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A phase II A study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone-Deacetylases inhibitor, in… (More)
Is this relevant?